## <sup>1</sup>**Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized**

## <sup>2</sup>**Therapeutic Strategies**

3 Mark Robertson-Tessi<sup>1</sup>, Joel S. Brown<sup>1</sup>, Maria I. Poole<sup>2</sup>, Matthew Johnson<sup>2</sup>, Andriy 4 Marusyk<sup>3</sup>, Jill A. Gallaher<sup>1</sup>, Kimberly A. Luddy<sup>1</sup>, Christopher J. Whelan<sup>3</sup>, Jeffrey West<sup>1</sup>, 5 Maximillian Strobl<sup>1</sup>, Virginia Turati<sup>1</sup>, Heiko Enderling<sup>1</sup>, Michael J. Schell<sup>4</sup>, AikChoon 6 Tan<sup>5</sup>, Terry Boyle<sup>6</sup>, Rikesh Makanji<sup>7</sup>, Joaquim Farinhas<sup>7</sup>, Hatem Soliman<sup>8</sup>, Dawn 7 Lemanne<sup>9, 10</sup>, Robert A. Gatenby<sup>7</sup>, Damon R. Reed<sup>11</sup>, Alexander R. A. Anderson<sup>1,\*</sup> and 8 Christine H. Chung<sup>2,\*</sup>

10 <sup>1</sup>Department of Integrated Mathematical Oncology, <sup>2</sup>Department of Head and Neck-11 Endocrine Oncology, <sup>3</sup>Department of Cancer Physiology, <sup>4</sup>Department of Biostatistics 12 and Bioinformatics, <sup>6</sup>Department of Pathology, <sup>7</sup>Department of Radiology, <sup>8</sup>Department 13 of Breast Oncology, <sup>11</sup>Department of Individualized Cancer Management; H. Lee Moffitt 14 Cancer Center and Research Institute, Tampa, Florida <sup>5</sup>Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 16 Salt Lake City, UT <sup>9</sup> Oregon Integrative Oncology, Ashland, Oregon 18 <sup>10</sup>Department of Medicine, University of Arizona, Tucson, Arizona <sup>20</sup>**Running Title**: Evolutionary Tumor Board for Novel Therapeutic Strategies <sup>22</sup>**Key words**: evolution, multi-disciplinary cancer care, adaptive therapy, mathematical 23 models, evolutionary therapy

## <sup>24</sup>**\*Co-Corresponding authors:**

- 25 Christine H. Chung, MD
- 26 Christine.Chung@Moffitt.Org
- 27 Alexander R. A. Anderson, PhD
- 28 Alexander.Anderson@Moffitt.Org
- <sup>29</sup>12902 Magnolia Dr. Tampa FL, 33612
- 

<sup>31</sup>**Potential Conflict of Interest**: HE holds U.S. Patent 63/279,994: Bayesian Framework 32 to Augment Tumor Board Decision Making (provisional), U.S. Patent <sup>33</sup>62/040,579: Predicting glioma treatment response (provisional), and U.S. Patent <sup>34</sup>62/944,804: Methods for prostate cancer intermittent adaptive therapy (provisional). TB 35 received Research funding support from Bristol Myers Squibb and has stock ownership 36 in Ionis Pharmaceuticals. HS received honoraria from AstraZeneca, Seattle Genetics, <sup>37</sup>Merck, and Novartis for serving in *ad hoc* scientific advisory boards. DRR received 38 honoraria from Springworks and Eisai for serving in Data Safety Monitoring Committee. <sup>39</sup>CHC received honoraria from Sanofi, Merck, Brooklyn ImmunoTherapeutic, Fulgent, <sup>40</sup>and Exelixis for serving in *ad hoc* scientific advisory boards. All other authors declared 41 no conflict of interest.

## <sup>43</sup>**ABSTRACT**

<sup>44</sup>The current paradigm of clinical trials treating patients until disease progression using 45 maximum tolerated dose does not account for the dynamic tumor-host-drug interactions 46 that result in acquired resistance. Here, we present the concept of an Evolutionary 47 Tumor Board (ETB) and report interim results from a prospective, non-interventional 48 pilot study in which novel therapeutic strategies based on evolutionary principles were 49 developed under the ETB framework. The ETB approach relies on an interdisciplinary 50 team that integrates clinical, preclinical, and theoretical knowledge and the application 51 of mathematical modeling to predict patient responses to different therapies, including 52 novel approaches derived from eco-evolutionary first principles. We have previously 53 proposed several evolutionary therapies that aim to enhance the efficacy of an overall 54 treatment regimen, using existing agents for a given disease. Key among these 55 evolutionary therapies is the idea of "first-strike second-strike", where different agents <sup>56</sup>are administered in sequence, and new strikes are applied as soon as the efficacy of 57 the previous strike is nearing a minimum, as opposed to waiting until progression is 58 identified on periodic imaging. This approach requires careful analysis of longitudinal 59 patient data coupled with predictive dynamics generated by mathematical models. Here <sup>60</sup>we describe the ETB process and the interim results from 15 patients enrolled in the 61 feasibility trial. In addition, we describe the challenges faced as well as the solutions 62 that can be implemented via improved modeling approaches, better patient data 63 collection, and a reassessment of how we understand tumor dynamics in the light of 64 evolutionary principles.

## <sup>66</sup>**INTRODUCTION**

<sup>67</sup>Cancer is one of the major public health concerns globally, and the American Cancer <sup>68</sup>Society estimates approximately 1,918,030 new cases will be diagnosed in the United 69 States alone in 2022<sup>1</sup>. With breakthrough advances in cancer screening, targeted 70 therapies, and immunotherapies, overall cancer mortalities have been decreasing. 71 However, cancer is still the second leading cause of death in the U.S., with an 72 estimated 609,360 people expected to die from cancer in 2022. Therefore, the 73 development of novel strategies to improve outcomes remains urgent.

75 The general paradigm of novel therapy development in currently "incurable" cancers (by 76 current standard of care) that are recurrent and/or metastatic with resistance to existing 77 treatments has been focused on molecular characterization of a tumor for targeted 78 therapies, leveraging immune checkpoint inhibition, and identifying predictive 79 biomarkers to select the most efficacious regimen. However, this approach benefits only <sup>80</sup>a limited number of patients with targetable genomic aberrations and tumors with 81 immune responsive phenotypes; furthermore, most of these patients exhibit transient 82 responses due to the evolution of acquired resistance over time. This limitation is, at 83 least in part, due to the lack of a comprehensive evaluation of the dynamic tumor-host-84 treatment interactions over time. Consideration of evolution under treatment selection 85 and subsequent changes in tumor phenotype is not a novel concept; nevertheless, 86 strategies for using this perspective to guide systemic therapies are lacking. Too often 87 oncology strategies are static. The prevailing clinical intervention is reactionary after 88 resistance develops, and not proactive to curtail evolutionary dynamics<sup>2</sup>. From the

89 development of the first cancer cell, natural selection favors phenotypes that increase 90 fitness and eliminates those that do not, and this process continues through therapy<sup>3,4</sup>. <sup>91</sup>We continue to select systemic therapies empirically based on the observable response <sup>92</sup>in the dominant population because we are often unable to account for resistant minor 93 populations during the treatments that will eventually lead to recurrence. For patients 94 with incurable cancers, we must better understand the evolutionary dynamics that lead 95 to the emergence and predominance of therapy-resistant phenotypes, eventually 96 rendering even initially useful therapies to be ultimately ineffective. This highlights our 97 currently inability to incorporate evolutionary dynamics into routine clinical treatment to 98 delay or avoid the emergence of treatment resistance. But what is a better way?

99

100 There are several concepts from evolution and ecology that can potentially address 101 these limitations. For example, Anthropocene species extinctions have commonly 102 occurred when a cataclysmic perturbation (first strike) spatially fragments a large 103 population into small remnant populations with less genetic diversity and increased 104 sensitivity to stochasticity that then become susceptible to what otherwise might be 105 survivable minor perturbations (second strikes, third strikes, etc.). This concept could be 106 leveraged to develop an "extinction treatment" regimen that aims to improve therapy by 107 using a "first-strike" agent to generate a "cataclysmic" response, followed by a sequence 108 of second-strike therapy agents that might offer patients the chance of cure or complete 109 response<sup>5</sup>. Furthermore, even if cure is not possible with such a sequence of strikes, 110 moving agents forward to apply them near the nadir of the previous strike has the

111 potential to foment greater overall tumor decline, and the dynamics of these diminished 112 tumor burdens may prolong survival.

<sup>114</sup>The vast majority of currently employed strategies against cancer can be considered as 115 first strikes. Practically speaking, first strikes are any intervention such as surgery, 116 radiation, or systemic therapy agent(s) that induce an observable response. Current first 117 strikes are evaluated by how large a response occurs (with partial or complete 118 responses seen as desirable) and how durable the response remains before 119 progression. In the current fixed maximum tolerated dose paradigm, the subsequent 120 therapy is not initiated until the observation of clear disease progression after the first 121 strike. However, changing therapies upon disease progression is far too late in eco-122 evolutionary terms. Clinical progression simply provides delayed proof of the 123 evolutionary and ecological recovery of cancer cell populations, often weeks or even <sup>124</sup>months (or years or more) after the fact. Instead, the second strike should occur when, 125 or even before, the cancer cell population is the smallest after the first strike. Second-126 strike therapies do not need to have a proven track record for producing a large tumor 127 response like first-strike agents. Importantly, any remnant cancer populations survived 128 by the first strike may have vulnerabilities (i.e., collateral sensitivity) to second-strike 129 agents $5.6$ .

130

<sup>131</sup>Application of extinction-based therapies poses two questions to practicing clinicians: 1) 132 what is the appropriate timing of the second strike? and 2) what therapeutic agent(s) 133 should be selected as the second strike? To address these fundamental questions, we

134 adapted the existing framework of the clinical tumor board that determines the best 135 treatment options using multidisciplinary approaches and formed the Evolutionary 136 Tumor Board (ETB), broadening the traditional tumor board to include the non-clinical 137 disciplines such as Cancer Biology, Evolutionary Biology, Mathematical Oncology, and 138 Bioinformatics. The ETB explicitly considers the ecological (changes in tumor burden 139 and distribution of tumors) and evolutionary (changes in the heritable characteristics of 140 the cancer cell populations) dynamics of cancer. We hypothesize that this ETB <sup>141</sup>approach can develop novel therapeutic strategies based on eco-evolutionary principles 142 that may provide longer lasting responses by using currently available drugs in new 143 ways.

144

145 At the heart of evolutionarily inspired cancer therapies, cancer is seen as a complex, 146 adaptive dynamic system governed by natural selection. Evolutionary therapies model 147 cancer cells within a tumor as an adapting and phenotypically heterogeneous 148 population. Central to capturing cancers' complex dynamics is patient-specific 149 mathematical modelling (e.g. using differential equations or game theory), with its ability 150 to exploit historic response data (for model calibration) and forecast future therapy  $151$  combinations and schedules<sup>7</sup>. Integrating clinical experience, completed clinical trial 152 data, retrospective patient data analysis, extensive literature review, and detailed 153 patient specific analysis facilitates a unique dialogue among the many involved 154 disciplines. This results in a patient-specific decision tool, driven by predictive 155 mathematical modeling, for evaluating the possible consequences of different treatment 156 options. Importantly, this approach allows for detailed reassessment of care decisions

157 as follow-up data is received during treatment. Here, we report a description of the ETB 158 workflow and framework, its feasibility, and the interim results of this pilot study.

<sup>160</sup>**METHODS** 

## <sup>161</sup>**Study Design and Patient Selection**

162 The prospective, non-interventional pilot study was conducted at Moffitt Cancer Center 163 under an IRB-approved protocol (MCC 20417, Feasibility of Generating Novel <sup>164</sup>Therapeutic Strategies based on Evolutionary Tumor Board, NCT04343365). 165 Institutional IRB approval was obtained in accordance with the Department of Health 166 and Human Services Federal Policy for the Protection of Human Subjects (US Common 167 Rule) at Moffitt Cancer Center. The study was initiated after the IRB approvals and 168 written consents were obtained. Patients were eligible for enrollment if they were 169 deemed to be incurable given the current standards of care, had a life expectancy over <sup>170</sup>3 months, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, 171 had a primary oncologist willing to consider the therapeutic strategies recommended by 172 the ETB, and were willing to be followed over time and allowing clinical data collection 173 over time. This includes patients in remission but at high risk of recurrence, patients with 174 suboptimal responses to previous therapy, or patients with many potentially beneficial <sup>175</sup>(but not curative) options for care. There were no exclusion criteria.

176

177 The primary endpoint of the study is to determine the rate of developing evolutionary-178 therapy-based treatment strategies for ETB-enrolled patients without curative options. <sup>179</sup>Exploratory aims include other potential results of this process: 1) To determine the rate

180 of implementing evolution-inspired plans by the treating physician through a chart 181 review; 2) To assess whether evolutionary strategies recommended by the ETB <sup>182</sup>improve prognosis compared to *a priori* prognosis for patients who have exhausted 183 curative strategies through a chart review; 3) To assess the feasibility to build and refine <sup>184</sup>mathematical models to explore duration of effect and survival for ETB 185 recommendations; 4) To assess the feasibility to analyze radiologic features of cancer 186 over time to predict duration of effect and survival for ETB recommendations; 5) To 187 assess whether changes in the circulating cell-free DNA (cfDNA) over time as a variable 188 is or is not informative in building mathematical models; 6) To assess whether presence 189 of certain tumor genomic abnormalities by whole exome sequencing as a variable is or 190 is not informative in building mathematical models; and 7) To assess the feasibility of 191 generating impact hypotheses based on evolutionary and/or ecological principles to 192 improved cancer therapy.

193

#### <sup>194</sup>**The ETB Process**

195 Once enrolled, a patient's disease history and treatment summary were compiled by the 196 oncologist and the ETB coordinator. The remaining options for care and anticipated 197 response rates along with prognosis in terms of progression-free survival (PFS) and 198 overall survival (OS) were annotated from the literature. Collected data points include 1) <sup>199</sup>demographics, 2) social history including alcohol and tobacco use history, 3) family 200 history, 4) Eastern Cooperative Oncology Group performance status, 5) pathology, 6) 201 any clinically relevant laboratory test and biomarker results, 7) prior therapies and 202 associated tumor measurements during the therapies, and 8) potentially available

203 subsequent therapies for consideration by the ETB. The tumor measurements were 204 obtained as 1-dimensional measurements using the RECIST v1.1 criteria as a guideline 205 and 3-dimensional measurements for volumetric quantification of all measurable 206 lesions. In addition, for the purpose of calibrating the model, we typically utilize 207 retrospective clinical data for the drugs under consideration for a given patient. For the 208 specific exemplar patient below, we used data from a phase II study of cetuximab and 209 nivolumab in recurrent and/or metastatic (R/M) head and neck squamous cell 210 carcinoma (HNSCC; NCT03370276). The detailed study population and results were 211 previously published $8,9$ .

212

213 For each patient, at least 2 preparatory discussion meetings occurred among a subset 214 of the key ETB members in advance to the ETB meeting, consisting at least of primary 215 oncologists that oversee the treatment implementation of the patient being discussed, 216 mathematical modelers, preclinical experimentalists, ecologists, radiologists, and often 217 other oncology disciplines and additional *ad hoc* members. During these discussions, 218 the current clinical standard was discussed along with alternatives. Evolutionary 219 strategies were proposed to establish what interventions were possible and what 220 measurements of responses were feasible. Predictions from a patient-calibrated 221 mathematical model and several iterations of the clinical questions in response to them 222 often occurred during the generation of the ETB recommended treatment plan.

<sup>224</sup>The ETB itself was convened monthly and consisted of clinical oncologists (surgical, 225 radiation, medical, and pediatric), radiologists, pathologists, evolutionary biologists,

226 mathematicians, research scientists, statisticians, data scientists, and clinical trial-227 related personnel at Moffitt Cancer Center. The primary oncologist typically started by 228 presenting their case to the multidisciplinary ETB, followed by the mathematical 229 modelling team presenting the process and initial thoughts and plans for the patient. 230 The interdisciplinary discussion that followed often refined and sometimes changed a 231 therapeutic strategy, and also generated hypotheses that influenced directions for follow 232 up preclinical work, future clinical trials, or other areas of investigation.

#### <sup>234</sup>**RESULTS**

## <sup>235</sup>**Patient Characteristics**

236 A total of 15 patients were enrolled to the ETB protocol between 5/5/2020 and 4/7/2022. <sup>237</sup>As described below, we also used a retrospective cohort to calibrate the model. This 238 cohort consisted of a total of 26 patients with HNSCC and were obtained from the 239 phase II clinical trial of cetuximab and nivolumab<sup>8,9</sup>. The patient characteristics for the <sup>240</sup>ETB and retrospective patients are summarized in **Table 1**. The prior line of therapy is 241 defined as the number of treatment regimens that the patient received from the time of 242 recurrent and/or metastatic disease diagnosis. Most patients were heavily treated 243 before enrolling to the trial, but 14 of 15 (93%) patients had good performance status 244 with ECOG PS 0-1.

245

## <sup>246</sup>**Development of Therapeutic Strategies based on Mathematical Modeling**

247 The overall ETB workflow is summarized in Figure 1A. Each individual patient's history 248 was collected based on the protocol requirement and summarized. Examples of the 249 prior treatment history and data collection along with available treatment options and

<sup>250</sup>their estimated outcome are shown in **Supplemental Table 1** and **Supplemental Table**  <sup>251</sup>**2**. The collected data were graphed to visualize an accurate timeline of disease burden 252 based on the radiographical imaging studies, drug dosing, and all sequences of 253 previous treatments (**Figure 1B**). If imaging data informed tumor burden, then the 254 volume dynamics, appearance, and disappearance of each lesion were also included. 255 Aggregating this information into a standardized visual treatment and response chart 256 has proved to be an invaluable tool for ETB discussion.

258 The available clinical data points were integrated to calibrate mathematical models that 259 explore treatment options using a system of ordinary differential equations (ODEs). The 260 equations have sufficient complexity to capture the key disease dynamics observed in 261 patients and remain simple enough to avoid overfitting (**Figure 1C**). Data available for 262 each individual patient tend to be sparse in terms of the number of time points, and thus 263 unsuitable for fitting models with numerous parameters<sup>10</sup>. In our primary model, termed 264 the GDRS model, we focus on four aspects of tumor dynamics: tumor Growth, tumor 265 Death, evolution of drug Resistance, and drug re-Sensitization. The model is an 266 extension of a tumor-growth inhibition model<sup>11-14</sup> and consists of  $n+m$  differential 267 equations, where *n* is the number of distinct lesions, and *m* the number of drugs that are 268 administered. We let  $T_i$  be the volume of lesion  $i=1,...n$ ; and  $D_i$  be the dose (as a 269 function of time) of drug  $j=1,...,m$ . The efficacy of each drug over time  $(E_i)$  is distinct for 270 each drug, and changes to reflect the evolution of resistance or subsequent 271 resensitization. In the following equations,  $T_i$ ,  $D_i$  and  $E_j$  are time-dependent:

$$
\dot{T}_i = \left(\begin{array}{c}\n\text{Freatment response} \\
\hat{V}_i - \sum_j \delta_j E_j D_j \\
\vdots \\
\hat{E}_j = \left(\frac{\text{Sensitization}}{\hat{s}_j (1 - E_j)(1 - D_j)} - \sum_j^{\text{Evolution of Resistance}} \hat{V}_j \right) E_j \\
D_j = D_j(t)\n\end{array}\right)
$$

272 In this eco-evolutionary model,  $T_i$  models the ecological dynamics,  $E_i$  the evolutionary 273 dynamics, and  $D_i$  the choices of the physician and patient. The model is further <sup>274</sup>described in **Supplemental File 1**.

#### <sup>276</sup>**Model Calibration using ETB Patient Specific Data**

277 To apply the model to an ETB patient's data, we made the following assumptions. First, 278 we assumed that all the lesions within a patient shared the same growth parameter  $(y_i)$ 279 unless there were significant indications from the data suggesting that a particular lesion 280 should have its own individualized fit. Thus, tumors within a patient only differed in 281 terms of their date of first appearance and initial size. When possible, growth rates were 282 calculated from a pair of consecutive increasing volumetric measurements for a lesion. <sup>283</sup>These pairs of points were picked with the following prioritization scheme: 1) two <sup>284</sup>measurements for the primary lesion prior to initial therapy; 2) two measurements for 285 any metastatic lesion while off therapy; 3) maximal growth rate found within all 286 increasing sequential measured volumetric pairs regardless of therapy status. In cases 287 where multiple pairs of points satisfied the same level from the prioritization scheme, the <sup>288</sup>maximal growth rate was used as the baseline. The growth rate, γ, thus derived is set to

289 be the exponential growth parameter for the patient as a whole, for all lesions. An 290 exception arises if one or more lesions are clearly significantly different in its growth 291 rates, in which case the outlier lesion is given its own growth rate  $v_i$ .

293 An additional factor can affect the growth rates, namely the appearance of new lesions 294 relative to the dates of patient scans. When a new lesion is detected, the volume is 295 noted. Following that, the previous scan of that same area is rechecked for any prior 296 evidence of that lesion. This is a relevant check as the threshold for identifying a lesion <sup>297</sup>*de novo* is larger than identifying it *post hoc*, when the location is now known from later 298 scans. In either case, imaging has a lower limit of measurable size determined by 299 contrast, voxel size, etc. When tracing a new lesion back through previous scans, 300 eventually a scan is reached where there is no evidence of that lesion. For the model, 301 we set its initial size in accordance with the minimal detection size of the instrument. <sup>302</sup>Thus, this may be an over-estimate and consequently may underestimate the tumor's 303 growth rate when calculated from the next scan, where the lesion was identified and <sup>304</sup>measured. In some cases, this underestimate may still be higher than the growth rates 305 measured from other lesions, in which case the new lesion may receive its own higher 306 growth rate for fitting purposes. This approach of tracking individual lesions backwards 307 in time is a novel aspect of the ETB, allowing for the extraction of additional data 308 regarding the lesion dynamics that would otherwise not be available.

<sup>310</sup>To fully fit the drug-induced death and resistance parameters, at least two volumetric 311 measurements while on the same therapy are needed. In this case, the starting tumor

312 size (calculated from the pre-treatment scan), the growth rate, and the two on-treatment 313 time points are sufficient to fit the 'U-shaped' ecological dynamics of the tumors. The 314 model then reflects initial drug efficacy (drug-induced death rate,  $\delta$ ) followed by 315 increasing drug resistance. In cases where there is only one on-treatment 316 measurement, drug-induced death rate and rate of increasing drug resistance, *r*, cannot 317 both be estimated. In such cases, we specify a functional form that generates pairs of <sup>318</sup>parameters that fit the single on-treatment data point (**Supplemental File 1**). This 319 function defines a set of parameter pairs all of which fit the patient data points. In 320 principle, this set is wide-ranging, although biologically realistic bounds can be placed 321 on  $\delta$  and *r*, particularly using historical data from independent cohorts. The predictions 322 arising from the possible pairs of  $\delta$  and r can vary greatly. Thus, constraining the set of 323 plausible pairs is of high value for predicting the future course of the patient's disease.

## <sup>325</sup>**Model Calibration using Historical Data**

326 A key aspect of the ETB process is the use of retrospective cohort data to constrain the 327 predictions generated for the specific ETB patient. As such, we evaluated a <sup>328</sup>retrospective cohort of patients with recurrent and/or metastatic HNSCC (**Tables 1 and**  <sup>329</sup>**2**). For these 26 retrospective patients, we applied the ETB analysis approach to their 330 available historical data. Imaging scans were retrieved and remeasured to both 331 generate volumetric measures of each lesion and look for non-target lesions that may 332 not have been considered during typical RECIST follow-up analysis at the time of their 333 care. These data were then modeled using the above procedures to find parameter 334 ranges for each patient that matched their data. Specifically, ranges of growth rates for

335 lesions (γ), their response to any applied therapies ( $\delta$ ), and their rate of becoming 336 resistant to such therapies (*r*) were determined. These ranges give a starting point for 337 predicting the outcomes of the ETB patient, putting expected bounds on their growth 338 rate and response to treatments, wherever the ETB patient's data itself does not offer a 339 fit. In our exemplar patient that we describe below, we used the retrospective cohort of 340 patients receiving combination cetuximab and nivolumab to predict the widest range of 341 response to these agents expected in the ETB patient. The patient's own lesion 342 dynamics then further refines the predictions within that retrospective range of 343 possibilities.

344

## <sup>345</sup>**Evaluation of Primary Endpoint of the Pilot Study**

<sup>346</sup>In 15 patients enrolled to date, 11 patients (73%) met the primary endpoint (**Table 3**). In <sup>347</sup>cases where the end point was not met, the reasons are: 1) the patient was deceased 348 before the date of the first ETB presentation, 2) insufficient historical data/analysis at the 349 time of ETB to predict response to additional therapy options, 3) the patient was taken 350 off the study at physician's discretion before the ETB presentation, and 4) the patient did 351 not have measurable lesions delaying the presentation at ETB. In the 11 cases with 352 recommendations, subsequent systematic chart reviews were conducted to determine if 353 the treating physician altered the patient's treatment plan based on the evolutionary 354 therapies recommended by the ETB. The physician and patient followed the 355 recommendation of the model in all 11 cases. All patients were longitudinally followed 356 on the protocol for continued chart review to evaluate, after sufficient follow up, whether

357 the patient had an improved outcome compared to the *a priori* prognosis for similar 358 patients under standard of care.

<sup>360</sup>The ETB has developed a framework to evaluate novel therapeutic strategies for 361 individual patients, including tools for temporal visualization of the treatment and 362 responses throughout the patient's cancer journey, and application of the GDRS model 363 to volumetric and other biomarker data. These tools are critical in facilitating treatment 364 decisions for each individual patient in an efficient and consistent manner. Due to the 365 often-sparse nature of clinical data, and need to constantly refine treatment decisions, 366 we developed the following decision support workflow for fitting, prediction, and analysis 367 using the ETB framework (**Figure 2A**).

### <sup>369</sup>**Evaluation of HNSCC based on the ETB recommendation**

370 To determine the initial feasibility of the ETB based approach, we focused on the 371 evaluation of HNSCC because of the immediate availability of the retrospective cohort 372 through a recently completed clinical trial. Parallel efforts for each enrolled patient in 373 other disease sites to develop a similar model is ongoing and will be reported 374 separately. For HNSCC, we enrolled a man in his 60's with an initial diagnosis of <sup>375</sup>HNSCC (subject ID: ETB-003) with base of tongue primary site and cervical lymph node <sup>376</sup>metastasis based on imaging studies. The patient pursued non-standard of care <sup>377</sup>alternative therapy and had local disease progression **(Supplemental Table 1)**. The 378 repeat biopsy of cervical lymph node at the time of disease progression was p16-379 positive squamous cell carcinoma. The patient started palliative chemotherapy with

380 cisplatin, 5-fluorouracil, and cetuximab. Unfortunately, the regimen was discontinued 381 because of toxicity after one cycle. Pembrolizumab was started, and chemotherapy was 382 added due to disease progression on the pembrolizumab monotherapy. Again, the <sup>383</sup>treatment was discontinued due to toxicities. The patient completed the concurrent 384 carboplatin, paclitaxel, and radiation for durable locoregional control. The patient 385 developed disease progression locally and distantly with lung metastasis and was 386 treated with cetuximab and nivolumab.

<sup>388</sup>For this patient with metastatic relapse, we analyzed the potential outcomes that might 389 arise with the application of first-strike second-strike therapy, also known as extinction <sup>390</sup>therapy (**Figure 2B and Figure 2C**). Upon relapse, the patient was put on the 391 combination of cetuximab and nivolumab (the first strike), which we label F1 here. The 392 goal of our analysis was to determine when the patient might fail this combination and 393 therefore intervene at the appropriate time with a second strike. In this case, there were 394 two chemotherapy options available as second strikes: carboplatin plus paclitaxel (S1) 395 and cisplatin plus 5-fluorouracil (S2). Ideally, the first strike will be applied until efficacy 396 wanes and the nadir of tumor burden is near, at which point the switch to the second 397 strike would occur. In our analysis of this patient, we used retrospective cohort data, the 398 patient's previous imaging data, and the temporal follow-up data to determine 1) when 399 the nadir of F1 may occur, and 2) which of the second strikes to switch to.

## <sup>401</sup>**Initial analysis and model fits**

<sup>402</sup>**Figure 2B** shows the initial analysis of the patient that was produced after enrollment. <sup>403</sup>The dynamics of their lesions pre-ETB are shown to the left of the solid vertical line, 404 which represents the time at which the patient was first analyzed by the ETB. Some of 405 the early historical data was not available since the patient was treated at another 406 institution prior to being seen at Moffitt Cancer Center. Volumetric measurements for all 407 available scans were performed retrospectively for each detectable lesion and are 408 shown as dots on the plot. The horizontal time axis is scaled relative to the first 409 available scan.

410

411 The patient was administered several different therapies to address the primary 412 disease: combination regimens of chemotherapies, targeted therapy, immunotherapy, 413 and radiotherapy, with the latter causing regression of the primary disease around day <sup>414</sup>760. A follow-up scan on day 878 showed no evidence of disease; however, on day 415 1026 there was evidence of lung and lymph node metastases. These were measured 416 volumetrically. Knowing their positions in the lungs, the previous scan with no evidence 417 of disease (NED) at day 878 was reexamined to see if very small lesions were indeed 418 detectable, but they remained NED. Therefore, we consider that these lesions are 419 smaller than the detection threshold of the instrument, and they are marked with 'x' 420 markers on **Figure 2B**. Shortly before enrolling on the ETB, the patient began their first-421 strike therapy  $(F1)$  for the metastatic disease.

422

<sup>423</sup>In accordance with the methods, we fit the model to the available data. The growth rate 424 ranges were primarily fit from the metastatic disease dynamics, since there were two 425 measurements prior to starting therapy F1, and an additional upper limit from the NED 426 scan on day 878. Using these ranges of growth rate, we fit efficacy and resistance 427 parameters for the dynamics of the primary disease (of which a representative fit for the <sup>428</sup>largest primary lesion is shown in **Figure 2B** in dark blue). A confounding factor is that 429 the drugs were primarily given in combination, and furthermore the imaging data is 430 sparse compared to the multiple changes of agents. However, some constraints on the 431 drug behaviors can be gained from these fits.

432

433 We also leveraged our retrospective data for the first-strike therapy from patients having <sup>434</sup>received the same F1 combination of cetuximab and nivolumab, from the clinical trial 435 described above. By fitting to the dynamics of the patients in that cohort, we determined <sup>436</sup>ranges of efficacy for F1 (**Table 2**). Application of this range to the current patient (using 437 the intrinsic range of growth rates and resistance rates found from their own lesion 438 dynamics) produced the predictive cone shown in light blue (the widest cone). Naturally, 439 since some retrospective patients progressed rapidly and others had significant 440 responses, the cone encompasses a wide range of possible responses for the current 441 patient. Taking the average retrospective behavior and applying it to the current patient 442 produces the darker shaded region.

<sup>444</sup>At this stage of the analysis and patient decision-making process, we are primarily 445 interested in knowing when the efficacy of F1 will be significantly diminished, and

446 therefore the nadir of tumor volume will be approached. This will be the time to switch to 447 a second strike. The time-to-nadir (TTN) for the retrospective cohort parameter ranges 448 applied broadly to this patient ranges from 0 months (i.e., the efficacy of F1 is low 449 enough that the lesions are already growing through it) to 7.3 months. To refine the 450 patient-specific prediction of the nadir, we leverage model fits derived from the earlier 451 lesion dynamics, and restrict the fits generated by the retrospective cohort parameter 452 ranges to those that match the current patient's fits. After this constraint, the model 453 predicts that the current patient is likely to do significantly better than the average 454 response of the retrospective cohort. The likely TTN range is now between 4.2 months 455 and 6.9 months. Since the next scan is anticipated to be within two months of starting 456 the therapy, the model strongly suggests that switching therapies should wait until 457 follow-up imaging is obtained.

## <sup>459</sup>**First follow-up analysis**

460 Upon imaging and performing volumetric measurements of the lesions, we reanalyze <sup>461</sup>the patient dynamics. **Figure 2C** shows the results after the first follow-up scan for the 462 patient at day 1119. The largest lesion has declined significantly under the first strike, <sup>463</sup>F1. This decline was in line with the "Patient fit" prediction cone of **Figure 2B**, 464 suggesting that the growth rates and treatment dynamics determined from earlier 465 timepoints remained consistent for this lesion over time. The updated prediction cone 466 for F1 is narrower after follow-up analysis using the additional data point. The TTN now 467 ranges from 1.5 to 3.5 months (from the time of follow-up, not the start of F1). The <sup>468</sup>model again suggests that the first strike is most likely to remain efficacious until the

469 next imaging cycle, with only a small fraction of simulations suggesting that the nadir will 470 be reached prior to that time.

472 At the same time, we examine what the effect of switching to a second strike would be 473 at this time, since we do not want to wait until the nadir is reached to switch. In the <sup>474</sup>insets of **Figure 2C**, we show the predicted range of effect for switching from the F1 to 475 either second-strike S1 (inset A) or S2 (inset B). In both cases, the range of efficacy for 476 the strike is determined by both retrospective cohort responses and the current patient's 477 response, since they were previously administered these agents during primary tumor 478 treatment. S1 was administered at the end of the primary disease treatment, and 479 therefore the estimates are better than for S2, which was only administered in 480 combination with other agents, and therefore has confounding factors in the primary fits. 481 However, in both cases, the model suggests that compared to staying with the first 482 strike, the second strikes appear to bring no advantage at this time. Therefore, since the 483 model predicts that there is likely some efficacy remaining in F1 and that both S1 and 484 S2 currently provide little comparative advantage, the decision is to continue the therapy 485 until the next imaging time point.

486

#### <sup>487</sup>**Second follow-up analysis**

488 For any patient in follow-up, the ETB process repeats with each new scan. Volumetric 489 measures for the next follow-up scan were attained and the updated analysis is shown 490 in Figure 2D. The tumor has continued to shrink, albeit at a slower rate than during the 491 initial phase. Reanalyzing the data with the model leads to updated predictions for the

TTN, which now ranges from 0 to 1.7 months (from the reanalysis time point). This suggests that the efficacy of F1 is approaching its end. The insets in the figure show the predicted efficacy of the two second-strike options, and as opposed to **Figure 2C**, both 495 now are likely to have a better effect on tumor burden than continuing with F1.

496

### <sup>497</sup>**Decision support in the ETB**

498 The ETB is a non-interventional trial, and therefore the decisions of when to switch 499 therapies and what to switch to remain in the hands of the oncologist and the patient. 500 Here, the model analysis and predictions used in the ETB workflow aim to give insight 501 into the temporal dynamics of the patient's specific disease, which can aid in making the 502 above decisions. In the exemplar case above, the model initially suggested continuing 503 the first strike, and similarly continuing after the first follow-up imaging point, after which 504 the model began to suggest that a second-strike option should be applied soon. For this 505 patient, an additional treatment option, radiotherapy, arose at the time, and was chosen 506 as a second strike. The insight gained regarding the efficacy and expected nadir of the 507 first strike was valuable in making the subsequent treatment decisions for the patient.

#### <sup>509</sup>**DISCUSSION**

510 Here we report the first results of the ETB feasibility study, having built a system to 511 capture available clinical tumor dynamics over time and in response to available 512 therapies, to incorporate the remaining conventional therapeutic options, and created a 513 forum and methodology for disciplines with an evolutionary understanding of cancer to 514 discuss ideas and implement them for patients. We also highlight a specific patient to

515 provide more detail of the process of building a model and using it to guide timing and 516 selection of available therapies in a novel and dynamic manner. We leveraged the 517 existing framework of clinical tumor boards, the well-established best practice care 518 delivery model in oncology, in combination with quantitative analysis<sup>7,15</sup>. ETB uniquely 519 includes non-clinical disciplines and integrates eco-evolutionary concepts to generate 520 novel treatment strategies and assesses the results of this platform over time.

<sup>522</sup>To date we have primarily analyzed patients with HNSCC while additional investigations 523 into adolescent and young adult sarcomas, prostate, breast, and lung cancers are 524 ongoing. Successfully expanding to additional disease sites depends on many factors. 525 A key aspect is having the option to change therapies in real time during follow-up. In 526 addition, availability of retrospective cohorts to inform model development is critical to 527 their utility. **Figure 3** shows how we envision the current incarnation of the ETB in 528 facilitating the integration of evolutionary therapies into standard practice. Early on, the <sup>529</sup>ETB serves as a test bed for developing models, understanding the evolutionary 530 dynamics of the disease, and creating potential clinical trials. In later stages, pilot trials 531 will be served by a robust framework using highly calibrated mathematical model(s) 532 developed for that trial. If successful, we envision developing disease-specific software <sup>533</sup>modules that will assist the oncologist in decision support during standard of care, 534 particularly in practice environments without access to multidisciplinary tumor board. 535 This long-term vision delivers the insights gained from mathematical modeling of 536 evolutionary dynamics into the hands of any interested oncologist for personalized 537 decision support.

538

539 The ETB invites consideration of evolutionarily enlightened therapy approaches. Our 540 primary focus here has been using multi-strike therapy to effect maximal tumor 541 reduction, ideally extinction, while minimizing the effect of tumor resistance to any given 542 agent. Evolutionary theory suggests that it is best to switch therapies either just before 543 or at the nadir of the tumor volume under the current therapy (as opposed to waiting for 544 progression to occur and be observed on imaging) because the nadir is believed to 545 represent the point that the tumor population has effectively evolved resistance to the 546 first-strike therapy. A key tool in this approach is predictive modeling, which can 547 estimate time-to-progression before it occurs. In the best case, multi-strike therapy can 548 effect a cure, but even in the absence of such, the approach has the potential to deliver 549 deeper remission, both in terms of tumor volume and PFS.

551 There are several other eco-evolutionary concepts that are already in application or in 552 development. One of the more developed is adaptive therapy, which typically exploits 553 the evolutionary costs of resistance such as synthesis, maintenance, and operation of 554 the molecular machinery needed to survive treatment. The benefits of resistance 555 exceed costs during therapy. This has best been demonstrated thus far clinically in 556 prostate cancer<sup>16</sup> but also in preclinical models of breast cancer<sup>17</sup>. Adaptive therapy is 557 predicted to be most effective when there is a competitively dominant sensitive 558 population of cancer cells, typically present in clinical situations that have high response 559 rate but a low cure rate. It also requires a treatment strategy that reliably induces a 560 response. With continuous therapy or metronomic therapies that do not consider the

561 patient's tumor dynamics, competitively subordinate resistant cancer cells come to 562 predominate as they experience competitive release from the absence of the drugsensitive cancer cells<sup>18-20</sup>. By removing therapy while there is still a high frequency and 564 density of sensitive cells, these sensitive cells effectively compete with and therefore 565 suppress the resistant cancer cells. Adaptive therapy is an important and active area of 566 evolutionary therapy research<sup>16,17,19,21-32</sup> that can encompass multiple drugs<sup>31,32</sup> and has 567 already been considered for some ETB patients.

<sup>569</sup>We plan to initiate several clinical trials to better examine the ETB approach with 570 respect to accuracy, predictability, and outcomes. However, much work remains to be 571 done. First, the models will be improved with more real-world data, and thus increased 572 analysis of additional retrospective cohorts in each disease will serve to better constrain 573 the operating parameter ranges we apply in our models. Second, compared to imaging, 574 collecting additional biomarkers such as cfDNA has the potential to provide faster 575 turnaround, more frequent and even potentially more accurate information on tumor 576 dynamics, particularly in minimal residual disease states. Third, streamlining the 577 process of clinical annotation, literature searches, biomarker collection, analysis, and 578 prediction will be necessary to apply this labor-intensive workflow on a wider scale, 579 though having performed the process for a given diagnosis provides efficiencies for 580 future ETB patients. To this end, we are developing a framework that automates much 581 of the process from start to finish, allowing the ETB team to focus on key discussion 582 points regarding the model predictions and patient assumptions that drive the next 583 decision point. Ultimately, we hope to continue to improve the therapeutic paradigm of

- 584 clinical oncology application based on the insight gained from ETB. We anticipate the
- 585 tools generated will inform both sequences and strategies of multi-strike therapy across
- 586 a number of cancers and directly facilitate the likelihood of cancer extinction.

#### **REFERENCES**

- 1 Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. *CA Cancer J Clin* **<sup>72</sup>**, 7-33 (2022). https://doi.org:10.3322/caac.21708
- 591 2 Stankova, K., Brown, J. S., Dalton, W. S. & Gatenby, R. A. Optimizing Cancer Treatment Using Game Theory: A Review. *JAMA Oncol* **<sup>5</sup>**, 96-103 (2019). 593 https://doi.org:10.1001/jamaoncol.2018.3395
- 3 Gatenby, R. A. & Brown, J. Mutations, evolution and the central role of a self-defined **induces function in the initiation and progression of cancer.** *Biochim Biophys Acta* **1867,**
- 162-166 (2017). https://doi.org:10.1016/j.bbcan.2017.03.005
- 4 Gravenmier, C. A., Siddique, M. & Gatenby, R. A. Adaptation to Stochastic Temporal 598 Variations in Intratumoral Blood Flow: The Warburg Effect as a Bet Hedging Strategy. *Bull Math Biol* **<sup>80</sup>**, 954-970 (2018). https://doi.org:10.1007/s11538-017-0261-x
- 5 Gatenby, R. A., Zhang, J. & Brown, J. S. First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. *Cancer Res* 602 (2019). https://doi.org:10.1158/0008-5472.CAN-19-0807
- 6 Gatenby, R. A., Artzy-Randrup, Y., Epstein, T., Reed, D. R. & Brown, J. S. Eradicating metastatic cancer and the eco-evolutionary dynamics of Anthropocene extinctions. *Cancer Res* (2019). https://doi.org:10.1158/0008-5472.CAN-19-1941
- 7 Kim, E., Rebecca, V. W., Smalley, K. S. & Anderson, A. R. Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. *Eur J Cancer* **<sup>67</sup>**, 213-222 (2016). https://doi.org:10.1016/j.ejca.2016.07.024

- 8 Chung, C. H. *et al.* Concurrent Cetuximab and Nivolumab as a Second-Line or beyond **Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell** Carcinoma: Results of Phase I/II Study. *Cancers* **<sup>13</sup>** (2021). https://doi.org:10.3390/cancers13051180
- 9 Chung, C. H. *et al.* Phase II multi-institutional clinical trial result of concurrent cetuximab 614 and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. *Clin Cancer Res* (2022). https://doi.org:10.1158/1078-0432.CCR-21-3849
- 10 Brady, R. & Enderling, H. Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to. *Bull Math Biol* **<sup>81</sup>**, 3722-3731 (2019). 618 https://doi.org:10.1007/s11538-019-00640-x
- 11 Claret, L. *et al.* Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. *J Clin Oncol* **<sup>27</sup>**, 4103-4108 (2009). https://doi.org:10.1200/JCO.2008.21.0807
- 12 Claret, L. *et al.* Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. *J Clin Oncol* **31**, 2110-2114 (2013). https://doi.org:10.1200/JCO.2012.45.0973
- 13 Glazar, D. J. *et al.* Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma. *J Clin Med* **<sup>9</sup>** 627 (2020). https://doi.org:10.3390/jcm9072019
- 14 Glazar, D. J. *et al.* Early response dynamics predict treatment failure in patients with **recurrent and/or metastatic head and neck squamous cell carcinoma treated with** cetuximab and nivolumab. *Oral Oncol* **<sup>127</sup>**, 105787 (2022). https://doi.org:10.1016/j.oraloncology.2022.105787

- 15 Pasetto, S., Gatenby, R. A. & Enderling, H. Bayesian Framework to Augment Tumor Board Decision Making. *JCO Clin Cancer Inform* **<sup>5</sup>**, 508-517 (2021). https://doi.org:10.1200/CCI.20.00085
- 16 Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary
- dynamics into treatment of metastatic castrate-resistant prostate cancer. *Nat Commun* **<sup>8</sup>**,
- 1816 (2017). https://doi.org:10.1038/s41467-017-01968-5
- 17 Enriquez-Navas, P. M. *et al.* Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. *Sci Transl Med* **<sup>8</sup>**, 327ra324 (2016). https://doi.org:10.1126/scitranslmed.aad7842
- 641 18 Gillies, R. J., Flowers, C. I., Drukteinis, J. S. & Gatenby, R. A. A unifying theory of carcinogenesis, and why targeted therapy doesn't work. *Eur J Radiol* **81 Suppl 1**, S48- 50 (2012). https://doi.org:10.1016/S0720-048X(12)70018-9
- 19 Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. *Cancer Res* **69**, 4894-4903 (2009). https://doi.org:10.1158/0008-5472.CAN-08-3658
- 20 Gatenby, R. A., Brown, J. & Vincent, T. Lessons from applied ecology: cancer control using an evolutionary double bind. *Cancer Res* **<sup>69</sup>**, 7499-7502 (2009). https://doi.org:10.1158/0008-5472.CAN-09-1354
- 21 Brady-Nicholls, R. *et al.* Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. *Nat Commun* **<sup>11</sup>**, 1750 (2020). 651 https://doi.org:10.1038/s41467-020-15424-4

- 22 Brady-Nicholls, R. *et al.* Predicting patient-specific response to adaptive therapy in
- metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
- *Neoplasia* **<sup>23</sup>**, 851-858 (2021). https://doi.org:10.1016/j.neo.2021.06.013
- 23 Cunningham, J. *et al.* Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. *PLoS One* **<sup>15</sup>**, e0243386 (2020). https://doi.org:10.1371/journal.pone.0243386
- 24 Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R.
- A. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in
- Continuous and Adaptive Cancer Therapies. *Cancer Res* **<sup>78</sup>**, 2127-2139 (2018).
- 661 https://doi.org:10.1158/0008-5472.CAN-17-2649
- 25 Kim, E., Brown, J. S., Eroglu, Z. & Anderson, A. R. A. Understanding the potential benefits of adaptive therapy for metastatic melanoma. *bioRxiv*, 2020.2010.2016.343269 (2020). https://doi.org:10.1101/2020.10.16.343269
- 665 26 Kim, E., Brown, J. S., Eroglu, Z. & Anderson, A. R. A. Adaptive Therapy for Metastatic
- Melanoma: Predictions from Patient Calibrated Mathematical Models. *Cancers (Basel)* **13** (2021). https://doi.org:10.3390/cancers13040823
- 27 Mason, N. T. *et al.* Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. *Am Health Drug Benefits* **<sup>14</sup>**, 15-20 (2021).
- 28 Strobl, M. A. R. *et al.* Spatial structure impacts adaptive therapy by shaping intra-tumoral 671 competition. *bioRxiv*, 2020.2011.2003.365163 (2021). 672 https://doi.org:10.1101/2020.11.03.365163



- 676 30 West, J., Ma, Y. & Newton, P. K. Capitalizing on competition: An evolutionary model of
- competitive release in metastatic castration resistant prostate cancer treatment. *J Theor*

*Biol* **<sup>455</sup>**, 249-260 (2018). https://doi.org:10.1016/j.jtbi.2018.07.028

- 31 West, J. *et al.* Towards Multidrug Adaptive Therapy. *Cancer Res* **<sup>80</sup>**, 1578-1589 (2020). 680 https://doi.org:10.1158/0008-5472.CAN-19-2669
- 32 West, J. B. *et al.* Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate 682 Cancer: An Evolution-Based Strategy. *Clin Cancer Res* (2019). https://doi.org:10.1158/1078-0432.CCR-19-0006

# **Table 1. Patient characteristics**



ETB: evolutionary tumor board

HNSCC: head and neck squamous cell carcinoma

ECOG PS: Eastern Cooperative Oncology Group Performance Status R/M: recurrent and/or metastatic

## **Table 2. Retrospective head and neck squamous cell carcinoma cohort characteristics (N=26)**





# **Table 3. Evolutionary Tumor Board (ETB) Recommendations**



#### **Figure 1A.**



**Figure 1B.**

**ETB-003** 



**Figure 1C.**



**Figure 1. A:** Schematic diagram of the Evolutionary Tumor Board clinical workflow. **B:** An example of tumor volumetric data visualization in context of the clinical data. **C:** An

example of tumor volumetric data visualization based on a mathematical model using a system of ordinary differential equations in context of the treatment data.

# **Figure 2A.**











# **Figure 2D.**



**Figure 2. A:** Overview of the ETB mathematical modeling using the tumor Growth, tumor Death, evolution of drug Resistance, and drug re-Sensitization (GDRS) model and decision support workflow. **B:** The initial analysis of the patient. The bottom section of the figure shows the treatments received over time. The top section of plot shows the volumes of each lesion (different colors for each lesion) on a  $log_{10}$  scale, over time, with clinical data from imaging represented by dots, and model fits represented by lines. Here, the model fit for the largest primary lesion is plotted (purple), as well as for the largest lung metastasis (teal). The 'x' markers represent scans with no detectable volume for that lesion (below the detection threshold for the instrument, represented by the dashed line).

The vertical solid line represents the time when the first ETB for the patient occurred, and the vertical dashed line indicated the next expected date of imaging. The model is used to create a cone of outcomes (shaded areas). The wide cone represents the range of outcomes seen in retrospective patients; the inner shaded cones represent the average retrospective patient, and the patient-specific predictions for the current patient.

**C:** First follow-up analysis by the ETB (solid vertical line). This occurs shortly after the patient has received their first imaging scan on the current therapy. The new prediction cone is significantly narrowed, given the additional data point. Inset A shows the prediction cone for immediately switching therapy to carboplatin and paclitaxel (purple cone), and inset B shows the predictions if the patient were immediately switched to cisplatin and 5-FU. **D:** Second follow-up analysis by the ETB (solid vertical line). This occurs shortly after the patient's second scan on current therapy. As in **Figure 2C**, the prediction cones for the two options for second strikes are shown in the insets.



**Figure 3.** Three phases of the ETB. The development phase (red) is where models and evolutionary therapy approaches are developed for each specific disease setting based on available biomarkers. Retrospective cohorts are curated and analyzed. The second phase (blue) brings the ETB approach to disease-specific clinical trials, using a Phase 'i' virtual trial approach for patient decision support. Models and biomarker collection are refined, and patient cohorts are expanded. In phase three (green), validated approaches are deployed for broad clinical use, via custom software developed for the specific disease. This system can be self-improving with each patient that is seen via the approach, contributing valuable data and outcomes to the retrospective cohort for a given disease.